KLEMP WALTER V
KLEMP WALTER V's purchase track record
How the stock did after each of KLEMP WALTER V's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/23/2025 | MBRX | $250K | +48.9% | -41.5% | +14.2% |
| 12/26/2023 | MBRX | $130K | -51.8% | -63.8% | +14.5% |
| 11/25/2022 | MBRX | $58K | -2.3% | -55.1% | +4.5% |
| 11/16/2022 | MBRX | $134K | +27.5% | -37.5% | +5.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
MBRX Completes Phase 2/3 AML Trial Enrollment, Publishes Cardiac Safety. Moleculin Biotech finished enrolling patients in Part A of its Phase 2/3 MIRACLE study for Annamycin plus cytarabine, keeping the program on schedule for a Q1 2027 data readout. The company also released a peer‑reviewed cardiac safety analysis of Annamycin and presented preclinical data showing the drug can turn cold pancreatic tumors hot through immune‑mediated mechanisms. These updates reinforce the company’s progress in both AML and solid‑tumor indications.
Transaction History
| AMIX | ▲ Buy | Grant | 13,000 | — | 9/3/2026 | View on chart |
| MBRX | ▲ Buy | Open Market | 533,333 | — | 8/3/2026 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 360 | — | 6/22/2026 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 88 | $275 | 6/22/2026 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 150 | — | 6/20/2026 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 37 | $107 | 6/20/2026 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 7,001 | $3K | 11/4/2025 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 28,750 | — | 11/4/2025 | View on chart |
| MBRX | ▲ Buy | Open Market | 675,675 | $250K | 6/23/2025 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 8,990 | — | 6/22/2025 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 2,190 | $585 | 6/22/2025 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 3,750 | — | 6/20/2025 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 914 | $244 | 6/20/2025 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 1,667 | — | 6/16/2025 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 406 | $278 | 6/16/2025 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 982 | — | 7/2/2024 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 240 | $857 | 7/2/2024 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 8,990 | — | 6/22/2024 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 2,190 | $8K | 6/22/2024 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 3,750 | — | 6/20/2024 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 914 | $3K | 6/20/2024 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 1,667 | — | 6/16/2024 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 406 | $2K | 6/16/2024 | View on chart |
| MBRX | ▲ Buy | Open Market | 188,404 | $130K | 12/26/2023 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 13,204 | — | 7/11/2023 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 3,216 | $2K | 7/11/2023 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 14,717 | — | 7/2/2023 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 3,584 | $2K | 7/2/2023 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 56,250 | — | 6/20/2023 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 13,697 | $8K | 6/20/2023 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 6,088 | $3K | 6/16/2023 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 25,000 | — | 6/16/2023 | View on chart |
| MBRX | ▲ Buy | Open Market | 45,000 | $58K | 11/25/2022 | View on chart |
| MBRX | ▲ Buy | Open Market | 22,500 | $26K | 11/21/2022 | View on chart |
| MBRX | ▲ Buy | Open Market | 24,742 | $25K | 11/17/2022 | View on chart |
| MBRX | ▲ Buy | Open Market | 85,213 | $83K | 11/16/2022 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 3,215 | $5K | 7/11/2022 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 13,204 | — | 7/11/2022 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 14,717 | — | 7/2/2022 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 3,584 | $5K | 7/2/2022 | View on chart |
| MBRX | ▲ Buy | Option Exercise | 25,000 | — | 6/16/2022 | View on chart |
| MBRX | ▼ Sell | Tax Withholding | 6,088 | $8K | 6/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Autonomix Gets Positive FDA Feedback, Completes Pre-Submission Meeting
The company reported that the FDA gave positive feedback that supports a 510(k) clearance pathway for its product. It also completed a pre‑submission meeting with the agency regarding its transvascular sensing platform. These steps move the regulatory process forward and may affect the company's future prospects. The stock is currently near its $7.83 support level.
Autonomix Gets Positive FDA Feedback, Completes Pre-Submission Meeting. The company reported that the FDA gave positive feedback that supports a 510(k) clearance pathway for its product. It also completed a pre‑submission meeting with the agency regarding its transvascular sensing platform. These steps move the regulatory process forward and may affect the company's future prospects. The stock is currently near its $7.83 support level.